Pharmaceuticals

Surge In Personalized Treatments Fueling The Growth Of The Market Due To Advancements In Genomics And Targeted Therapies Is Supporting Development Across The Peptide Drug Conjugates Market

May 20, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Size Is Forecasted For The Peptide Drug Conjugates Market By 2030 Based On Its 2026 Value?

The peptide drug conjugates market size has expanded rapidly over recent years. This market is projected to increase from $3.64 billion in 2025 to $4.21 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 15.4%. The historical growth can be attributed to several factors including advancements in peptide chemistry, the limitations associated with conventional chemotherapy, a surge in oncology drug research, the expansion of targeted therapy platforms, and the increasing growth of biologics manufacturing.

The peptide drug conjugates market is poised for substantial expansion over the next few years. It is forecast to reach $7.44 billion in 2030, advancing at a compound annual growth rate (CAGR) of 15.3%. This projected increase during the forecast period is driven by factors such as a growing need for precision therapies, ongoing improvements in linker technologies, the widening scope of cancer indications, increased financial commitment to peptide drug development, and the growth of diagnostic-targeted conjugates. Notable trends expected in the forecast period encompass the increasing creation of targeted peptide conjugates, their expanding application in oncology therapeutics, a heightened emphasis on better drug selectivity, the proliferation of diagnostic peptide conjugates, and a rise in clinical trials for innovative conjugates.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24359&type=smp

What Market Drivers Are Helping Shape The Peptide Drug Conjugates Market Expansion?

The increasing need for tailored treatments is expected to propel the expansion of the peptide drug conjugates market in the foreseeable future. These therapies are medical interventions specifically designed for an individual’s distinct genetic profile, way of life, and specific disease traits, aiming for optimal results. The rise of personalized treatments is attributable to progress in genomics, which facilitates the identification of specific disease markers in individuals, enabling more accurate and potent therapies. Personalized treatments improve peptide drug conjugates by enabling the selection of particular peptides that target distinct disease biomarkers within patients, resulting in more accurate and efficient drug delivery. As an illustration, a report released in February 2024 by the Personalized Medicine Coalition, a US-based non-profit organization, indicated that the FDA approved 16 new customized medicines for individuals suffering from rare disorders in 2023, marking a significant increase from the 6 approvals in 2022. Consequently, the escalating demand for personalized treatments is set to stimulate the expansion of the peptide drug conjugates market.

What Segment Types Are Included In The Peptide Drug Conjugates Market Analysis?

The peptide drug conjugates market covered in this report is segmented –

1) By Type: Therapeutic, Diagnostic

2) By Therapy Area: Oncology, Immunology, Infectious Diseases, Other Therapy Areas

3) By Route of Administration: Intravenous, Subcutaneous, Other Routes Of Administration

4) By End User: Hospitals, Clinics, Pharmacies, Other End Users

Subsegments:

1) By Therapeutic: Monoclonal Antibodies (mAbs), Cytotoxic Agents, Immunomodulatory Agents, Targeted Therapies

2) By Diagnostic: Imaging Agents, Biomarker Targeting Agents

Which Trends Are Affecting The Peptide Drug Conjugates Market Framework?

Leading companies in the peptide drug conjugates market are concentrating on developing advanced treatment options, such as tumor-selective peptide drug conjugates, to improve treatment accuracy. These tumor-selective peptide drug conjugates are targeted therapies that use peptides engineered to specifically bind to cancer cells, allowing for the direct delivery of cytotoxic agents to tumors while minimizing harm to healthy tissue. For example, in March 2025, Cybrexa Therapeutics, a US-based oncology biotechnology company, released new preclinical data concerning its alphalex technology. This data emphasized the effectiveness of Cybrexa’s antigen-agnostic peptide-drug conjugate (PDC) platform in directly delivering potent microtubule inhibitors to tumor cells. This method successfully suppresses tumor growth and generates a durable anti-tumor immune response. The results showcase the potential of Cybrexa’s technology to enhance cancer treatment.

Which Companies Form The Competitive Landscape Of The Peptide Drug Conjugates Market?

Major companies operating in the peptide drug conjugates market are PeptiDream Incorporated, Cybrexa Therapeutics Inc., Oncopeptides Aktiebolag (AB), Soricimed Biopharma Inc., Angiochem Inc., ADC Therapeutics SA, Ambrx Inc., Araris Biotech AG, Adcytherix SA, ProteinQure Incorporated, Esperance Pharmaceuticals Inc., Protagonist Therapeutics Inc., PepGen Corporation, Curium US LLC, AstraZeneca PLC, Novartis AG, Italfarmaco Società per Azioni, BioNTech SE, Theratechnologies Inc., Zealand Pharma A/S

Access The Complete Peptide Drug Conjugates Market Report:

https://www.thebusinessresearchcompany.com/report/peptide-drug-conjugates-global-market-report

Which Region Stands As The Largest Contributor To The Peptide Drug Conjugates Market?

North America was the largest region in the peptide drug conjugates market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide drug conjugates market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Peptide Drug Conjugates Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=24359&type=smp

Browse Through More Reports Similar to the Global Peptide Drug Conjugates Market 2026, By The Business Research Company

Antibody Drug Conjugates Market Report 2026

https://www.thebusinessresearchcompany.com/report/antibody-drug-conjugates-global-market-report

Peptide Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report

Peptide Antibiotics Market Report 2026

https://www.thebusinessresearchcompany.com/report/peptide-antibiotics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795